Rouhollah KHODADUST, Aktan ALPSOY, Gozde UNSOY, Ufuk GUNDUZ

Poly (I:C)- and doxorubicin-loaded magnetic dendrimeric nanoparticles affect the apoptosis-related gene expressions in MCF-7 cells

Use of nanoparticles as drug carrier vectors has great potential to circumvent the limitations associated with chemotherapy, including drug resistance and destructive side effects. For this purpose, magnetic generation 4 dendrimeric nanoparticles were prepared to carry chemotherapeutic agent doxorubicin (G 4-DOX) and immune modulator polyinosinic:polycytidylic acid [Poly(I:C)]. As previously reported, DOX and Poly(I:C) was loaded onto G 4 nanoparticles (PIC-G 4-DOX). Cellular internalization study using confocal microscopy demonstrated high levels of cellular internalization of PIC-G 4-DOX nanoparticles by MCF-7 cells. This resulted in higher efficacy of PIC-G 4-DOX nanoparticles in killing MCF-7 breast cancer cells. Alteration in the expression levels of selected genes was determined by RT-qPCR analyses. Proapoptotic NOXA, PUMA, and BAX genes were upregulated, and SURVIVIN, APOLLON, and BCL-2 genes were downregulated, indicating the cell-killing effectiveness of PIC-G 4-DOX nanoparticles. Gene expression analysis provided some insights into the possible molecular mechanisms on cytotoxicity of DOX and Poly(I:C) delivered through G 4 magnetic nanoparticles. The results demonstrated that PIC-G 4-DOX can be useful for targeted delivery affecting apoptotic pathways, resulting in an advanced degree of cancer-cell-killing. They are promising for targeting cancer-cells because of their stability, biocompatibility, higher internalization, and toxicity.

Keywords:

Targeted drug delivery magnetic dendrimeric nanoparticles, Poly(I:C), doxorubicin, gene expression,

PDF

___

Abedi-Gaballu F, 2018, APPL MATER TODAY, V12, P177, DOI 10.1016/j.apmt.2018.05.002
Alessandrini F, 2018, NEOPLASIA, V20, P857, DOI 10.1016/j.neo.2018.06.008
An W, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00758
Asnani A, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.96753
Bansal M, 2020, NANOSCIENCE MED, V1, P297
Bello M, 2020, J MOL GRAPH MODEL, V96, DOI 10.1016/j.jmgm.2019.107514
Besch R, 2009, J CLIN INVEST, V119, P2399, DOI 10.1172/JCI37155
Chanphai P, 2017, CAN J CHEM, V95, P891, DOI 10.1139/cjc-2017-0115
Chen Y, 2011, INT J NANOMED, V6, P2321, DOI 10.2147/IJN.S25460
Chorna IV, 2005, EXP ONCOL, V27, P196 .
Da Silva CG, 2017, CANCER CHEMOTH PHARM, V80, P881, DOI 10.1007/s00280-017-3427-1
Davis JM, 2003, CLIN CANCER RES, V9, P1161
de Moraes GN, 2013, EUR J CELL BIOL, V92, P247, DOI 10.1016/j.ejcb.2013.08.001
Dudgeon C, 2012, ONCOGENE, V31, P4848, DOI 10.1038/onc.2011.644
Faversani A, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3666
Ghavami S, 2009, J MED GENET, V46, P497, DOI 10.1136/jmg.2009.066944
Kato H, 2006, NATURE, V441, P101, DOI 10.1038/nature04734
Kaur D, 2016, J NANOPART RES, V18, DOI 10.1007/s11051-016-3423-0
Kawai T, 2005, NAT IMMUNOL, V6, P981, DOI 10.1038/ni1243
Khandare J, 2005, BIOCONJUGATE CHEM, V16, P330, DOI 10.1021/bc0498018
Khodadust R, 2014, BIOMED PHARMACOTHER, V68, P979, DOI 10.1016/j.biopha.2014.10.009
Khodadust R, 2013, J NANOPART RES, V15, DOI 10.1007/s11051-013-1488-6
KIM SH, 1972, CANCER RES, V32, P323 .
Ling WH, 2019, J MATER RES, V34, P1828, DOI 10.1557/jmr.2019.129
Liu F, 2007, BIOL PHARM BULL, V30, P2279, DOI 10.1248/bpb.30.2279
Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
Mendes LP, 2017, MOLECULES, V22, DOI 10.3390/molecules22091401
MIRSKI SEL, 1987, CANCER RES, V47, P2594
Parker-Esquivel B, 2012, LANGMUIR, V28, P3860, DOI 10.1021/la203998r
Pedziwiatr-Werbicka E, 2013, COLLOID SURFACE B, V109, P183, DOI 10.1016/j.colsurfb.2013.03.045
Rouhollah K, 2013, J PHARM SCI-US, V102, P1825, DOI 10.1002/jps.23524
Salvador A, 2012, VACCINE, V30, P589, DOI 10.1016/j.vaccine.2011.11.057
Seth RB, 2005, CELL, V122, P669, DOI 10.1016/j.cell.2005.08.012
Sevenson S, 2012, ADV DRUG DELIVER REV, V64, P102, DOI 10.1016/j.addr.2012.09.030
SHEEHAN JC, 1961, J ORG CHEM, V26, P2525, DOI 10.1021/jo01351a600
Singal P, 2000, MOL CELL BIOCHEM, V207, P77, DOI 10.1023/A:1007094214460
Strasser A, 2011, EMBO J, V30, P3667, DOI 10.1038/emboj.2011.307
Sui BW, 2014, MOLECULES, V19, P11915, DOI 10.3390/molecules190811915
Sun RL, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.178798
Vince JE, 2010, EMBO J, V29, P1627, DOI 10.1038/emboj.2010.79
Vivek R, 2013, COLLOID SURFACE B, V111, P117, DOI 10.1016/j.colsurfb.2013.05.018
Vivek R, 2014, INT J BIOL MACROMOL, V65, P289, DOI 10.1016/j.ijbiomac.2014.01.054
Yacoub TJ, 2011, BIOPHYS J, V101, P378, DOI 10.1016/j.bpj.2011.06.015
Yoneda K, 2008, INT J ONCOL, V33, P929, DOI 10.3892/ijo_00000080
Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087
Yuan MM, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1262-5
Zhang S, 2014, ONCOTARGET, V5, P7183, DOI 10.18632/oncotarget.2293